Public company intelligence preview
SUMMIT THERAPEUTICS INC
33 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.
Snapshot
A narrow read on a much deeper workspace.
The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.
Insider compensation
Public aggregate: $23.5M average total compensation across covered insiders.
Governance movement
Public aggregate: 0 governance events in the last year.
Institutional ownership
Public aggregate: 210 holders from the latest quarter.
Restricted sales and governance
Public counts, not the investigation layer.
The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.
Market context
Basic quote context for the preview.
Company note
Context before the data.
Company Overview
Summit Therapeutics Inc. is a development-stage biotechnology company in the Healthcare sector and Biotechnology industry, focused on oncology, with ivonescimab as its lead product candidate. Its core work centers on multiple Phase III trials in non-small cell lung cancer and colorectal cancer, while it relies on external partners for manufacturing, clinical development support, and supply chain execution. The company has no commercial revenue yet and remains dependent on clinical progress, regulatory approval, and financing to advance toward a potential launch in its licensed territories.
Executive Compensation Practices
Executive compensation at Summit is likely heavily weighted toward equity-based incentives, which is common for pre-commercial biotechnology companies in the Healthcare sector. The filings show that modified performance-based stock option awards created unusually large non-cash stock-based compensation charges in 2025 and early 2026, suggesting management pay is tied to clinical and corporate milestones rather than current profitability. For researchers, the key compensation drivers are likely trial readouts, regulatory submissions and acceptance, enrollment milestones, and commercialization readiness, along with broader stock-price performance given the company’s dependence on equity financing.
Insider Trading Considerations
Insider trading patterns for a company like Summit may be especially sensitive to clinical catalysts, FDA interactions, and financing events, because the stock can move sharply on trial data and regulatory news. With a BLA already accepted and a PDUFA date set, insiders may face heightened trading restrictions around material nonpublic information tied to trial outcomes, labeling negotiations, and approval timing. The company’s heavy cash burn, ongoing need for capital, and reliance on future equity raises can also make insider transactions more informative, since purchases or sales may reflect management’s views on dilution risk, clinical confidence, and the probability/timing of commercialization.
Unlock the full SMMT insider intelligence workspace.
Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.